19.69

10.12% 1.81

Novocure Ltd (NVCR)

Overview News Price History Option Chain Financials Why NVCR Down? Discussions Forecast

Novocure Ltd stock is traded at $19.69, with a volume of 1.07M. It is up +10.12% in the last 24 hours and up +17.62% over the past month. NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Previous Close:

$17.88

Open:

$18.29

24h Volume:

1.07M

Relative Volume:

1.05

Market Cap:

$1.93B

Revenue:

$577.74M

Net Income/Loss:

$-149.78M

P/E Ratio:

-10.59

EPS:

-1.86

Net Cash Flow:

$-78.21M

1W Performance:

+16.79%

1M Performance:

+17.62%

6M Performance:

-14.95%

1Y Performance:

+65.32%

1-Day Range:

$18.00

$19.77

1-Week Range:

$16.30

$19.77

52-Week Range:

$11.29

$24.73

Novocure Ltd Stock (NVCR) Company Profile

Name

Novocure Ltd

Sector

Healthcare (1200)

Industry

Medical Devices (153)

Phone

44 (0)15 3475 6700

Address

NO. 4 THE FORUM, ST. HELIER

Employee

1,453

Twitter

@novocure

Next Earnings Date

2024-10-30

Latest SEC Filings

NVCR's Discussions on Twitter

Compare NVCR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NVCR Novocure Ltd	19.69	1.93B	577.74M	-149.78M	-78.21M	-1.86
ABT Abbott Laboratories	118.95	208.18B	41.22B	5.77B	6.49B	2.94
SYK Stryker Corp	388.14	148.70B	21.97B	3.59B	3.21B	6.74
BSX Boston Scientific Corp	90.75	133.32B	15.91B	1.79B	1.89B	0.82
MDT Medtronic Plc	86.27	111.27B	33.00B	4.29B	5.50B	2.71
EW Edwards Lifesciences Corp	72.07	42.66B	6.60B	4.16B	490.10M	2.34

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight
Aug-04-23	Initiated	SVB Securities	Outperform
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-05-23	Reiterated	H.C. Wainwright	Buy
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy
Feb-08-22	Initiated	Loop Capital	Buy
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-20-22	Upgrade	Truist	Hold → Buy
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line
Jul-01-21	Downgrade	Mizuho	Buy → Neutral
Apr-14-21	Downgrade	Wedbush	Neutral → Underperform
Jan-25-21	Reiterated	Piper Sandler	Overweight
Sep-23-20	Initiated	Northland Capital	Outperform
Sep-18-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-17-20	Downgrade	Truist	Buy → Hold
Jun-01-20	Resumed	Oppenheimer	Perform
May-01-20	Downgrade	Oppenheimer	Outperform → Perform
Apr-09-20	Downgrade	Evercore ISI	In-line → Underperform
Mar-05-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-02-20	Downgrade	Evercore ISI	Outperform → In-line
Jul-29-19	Upgrade	SunTrust	Hold → Buy
Jul-26-19	Downgrade	JP Morgan	Overweight → Neutral
Jul-26-19	Downgrade	Wedbush	Outperform → Neutral
Mar-20-19	Initiated	SunTrust	Hold
Nov-02-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jul-16-18	Initiated	Evercore ISI	Outperform
Apr-18-18	Reiterated	Mizuho	Buy
Feb-23-18	Reiterated	Mizuho	Buy
May-24-17	Upgrade	Wells Fargo	Market Perform → Outperform
Jul-29-16	Reiterated	Wedbush	Outperform
Jan-19-16	Initiated	Barclays	Underweight
Dec-02-15	Initiated	Deutsche Bank	Hold

View All

Novocure Ltd Stock (NVCR) Latest News

Nov 26, 2024

NVCR (NovoCure) Shares Outstanding (EOP) : 108.1 Mil (As of Sep. 2024) - GuruFocus.com

Nov 26, 2024

Nov 25, 2024

Novocure's SWOT analysis: FDA approval boosts cancer tech stock prospects - Investing.com

Nov 25, 2024

NovoCure (NASDAQ:NVCR) Receives Buy Rating from HC Wainwright - Defense World

Nov 25, 2024

Nov 24, 2024

NVCR (NovoCure) Growth Rank : 8 (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024

Nov 23, 2024

Connor Clark & Lunn Investment Management Ltd. Acquires 59,608 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Nov 23, 2024

Nov 22, 2024

FDA approves Novocure's new device for brain cancer treatment By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 21, 2024

Novocure secures FDA approval for add-ons to brain cancer treatment wearable - Yahoo Finance

Nov 21, 2024

Novocure’s HFE Transducer Arrays OK’ed with Optune Gio for Glioblastoma - MPO-mag

Nov 21, 2024

FDA approves Novocure's new device for brain cancer treatment - Investing.com

Nov 21, 2024

Novocure to Present Breakthrough TTFields Brain Cancer Treatment Data at SNO Meeting | NVCR Stock News - StockTitan

Nov 21, 2024

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma - Yahoo Finance

Nov 21, 2024

Nov 18, 2024

Can Novocure's PANOVA-3 Trial Of TTFields Therapy Electrify The Stock? - RTTNews

Nov 18, 2024

Nov 16, 2024

NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Nov 16, 2024

Nov 14, 2024

NovoCure (NVCR) Shares Cross Below 200 DMA - Nasdaq

Nov 14, 2024